Application of DWI in Diagnosis of Prostate Cancer

Different Models of Multiple B-value DWI and Their Applications in Diagnosis of Prostate Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04962269

Enrollment

103

Registered

2021-07-14

Start date

2013-06-12

Completion date

2018-06-21

Last updated

2021-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia, Prostate Cancer

Keywords

benign prostatic hyperplasia, Diffusion weighted imaging

Brief summary

This study compared the performance of different models of multiple b-value DWI in diagnosing prostate cancer.

Detailed description

Diffusion weighted imaging (DWI) plays an important role in the diagnosis and stratification of prostate cancer. Traditional DWI apply the apparent diffusion coefficient (ADC) to reflect the diffusion of tissue water, which is a parameter calculated by a monoexponential model with 2b values. In recent years, the development of multiple b-value DWI facilitates the appearance of many new mathematical models. Different models have different features, but their value of applications in prostate cancer still need to be confirmed. This study was aiming to: (1) compare the parameters derived from monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model between prostate cancer and benign prostatic hyperplasia; (2) compare the difference of these parameters between low-grade (Gleason score ≤ 3+4) and high-grade (Gleason score ≥ 4+3) cancer; (3) find whether these parameters derived from new models are superior to ADC derived from traditional monoexponetial model.

Interventions

DIAGNOSTIC_TESTMRI

monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

1. The exam including T1WI、T2WI and multiple b-value DWI. 2. Comfired by pathology as prostate cancer or benign prostatic hyperplasia in one month after the MRI exam.

Exclusion criteria

* 1.No Gleason score data. 2.Awful quality of imagings or artifacts affectting diagnosis. 3.No lesion larger than 0.5cm. 4.Any surgery or treatment before MRI exam. 5.Biopsy in 4 weeks before MRI exam.

Design outcomes

Primary

Measure	Time frame	Description
pathological diagnosis	2013.10-2018.6	prostate cancer or benign prostatic hyperplasia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026